BioLineRx (NasdaqCM:BLRX) Earnings Call Presentation

GLIX1 Development - A joint venture with Hemispherian AS was established in September 2025 to develop GLIX1 for glioblastoma and other indications, with initial economic stakes of Hemispherian at 60% and BioLineRx at 40%, potentially increasing to 70% for BioLineRx [7, 8] - GLIX1 is set to begin Phase 1 development in H1 2026 and has received FDA IND clearance [8, 58] - GLIX1 enhances TET2 activity, leading to increased 5hmC levels and double-stranded DNA breaks in cancer cells, ultimately causing cell death [19, 24] - Preclinical data indicates GLIX1 shows efficacy in various cancer cell lines and addresses key challenges for GBM drug development, including good blood-brain barrier penetration [30, 44, 49] - A Phase 1/2a clinical trial for GLIX1 in recurrent and progressive GBM is expected to initiate in Q1 2026, with potential expansion cohorts for newly diagnosed GBM and combination therapy with PARPi [55, 57] Motixafortide and APHEXDA - APHEXDA (motixafortide) has been successfully developed and out-licensed for stem cell mobilization in multiple myeloma [4] - License agreements for APHEXDA include up to $87 million in commercial milestones and royalties on sales from 18%-23% in Asia, and up to $200 million in commercial milestones with tiered double-digit royalties on sales outside of Asia (excluding solid tumors) [5, 6] - In first-line PDAC, the Chemo4MetPanc pilot phase 2 clinical trial showed a 64% Overall Response Rate and a median PFS of 96 months [84, 89] - The Chemo4MetPanc randomized phase 2b clinical trial is ongoing, equally funded by Regeneron and BioLineRx, with full enrollment planned in 2027 [90, 94] Financial Status - The company reported cash of approximately $282 million as of June 30, 2025, with a cash runway into the first half of 2027 [96]